Immunomedics Inc (IMMU) - Financial and Strategic SWOT Analysis Review

September 2020 | 52 pages | ID: I9FFAF93FB6EN
GlobalData

Abstracts

Immunomedics Inc (IMMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Immunomedics Inc (Immunomedics) is a biopharmaceutical company that discovers, develops, manufactures and commercializes monoclonal antibody drug conjugates for the treatment of cancer and autoimmune disorders. It offers Trodelvy, which is indicated for the treatment of metastatic triple-negative breast cancer (mTNBC) in adult patients who were previously treated with at least two therapies for metastatic disease. The company is investigating its lead product candidate, Sacituzumab govitecan (IMMU-132) for the treatment of patients with mTNBC, metastatic urothelial cancer, hormone receptor-positive (HR+) or human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC), and others. Immunomedics is advancing IMMU-130 (labetuzumab govitecan) for colorectal cancer and IMMU-140 for hematologic cancers. It develops candidates based on its proprietary technologies namely, ADC Linker technology. Immunomedics is headquartered in Morris Plains, New Jersey, the US.

Immunomedics Inc Key Recent Developments

Aug 05,2020: Immunomedics reports second quarter 2020 results and provides corporate update
May 27,2020: Immunomedics announces leadership change and provides business update amid COVID-19
May 06,2020: Immunomedics reports first quarter 2020 results and provides corporate update
Apr 06,2020: Immunomedics announces executive leadership changes and the appointment of Harout Semerjian as president and chief executive officer
Mar 25,2020: Immunomedics provides COVID-19 business continuity update, affirm 2020 strategic priorities, and shares R&D and regulatory update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Immunomedics Inc - Key Facts
Immunomedics Inc - Key Employees
Immunomedics Inc - Key Employee Biographies
Immunomedics Inc - Major Products and Services
Immunomedics Inc - History
Immunomedics Inc - Company Statement
Immunomedics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Immunomedics Inc - Business Description
R&D Overview
Immunomedics Inc - Corporate Strategy
Immunomedics Inc - SWOT Analysis
SWOT Analysis - Overview
Immunomedics Inc - Strengths
Immunomedics Inc - Weaknesses
Immunomedics Inc - Opportunities
Immunomedics Inc - Threats
Immunomedics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Immunomedics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 05, 2020: Immunomedics reports second quarter 2020 results and provides corporate update
May 27, 2020: Immunomedics announces leadership change and provides business update amid COVID-19
May 06, 2020: Immunomedics reports first quarter 2020 results and provides corporate update
Apr 06, 2020: Immunomedics announces executive leadership changes and the appointment of Harout Semerjian as president and chief executive officer
Mar 25, 2020: Immunomedics provides COVID-19 business continuity update, affirm 2020 strategic priorities, and shares R&D and regulatory update
Feb 27, 2020: Immunomedics reports fourth quarter and full year 2019 results and provides corporate update
Feb 27, 2020: Immunomedics appoints Robert W. Azelby to board of directors
Feb 14, 2020: Immunomedics appoints Dr. Loretta Itri Chief Medical Officer
Oct 30, 2019: Immunomedics reports third quarter 2019 results and provides corporate update
Aug 07, 2019: Immunomedics reports second quarter 2019 results and provides corporate update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Immunomedics Inc, Key Facts
Immunomedics Inc, Key Employees
Immunomedics Inc, Key Employee Biographies
Immunomedics Inc, Major Products and Services
Immunomedics Inc, History
Immunomedics Inc, Subsidiaries
Immunomedics Inc, Key Competitors
Immunomedics Inc, Ratios based on current share price
Immunomedics Inc, Annual Ratios
Immunomedics Inc, Annual Ratios (Cont...1)
Immunomedics Inc, Interim Ratios
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Immunomedics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Immunomedics Inc, Performance Chart (2015 - 2019)
Immunomedics Inc, Ratio Charts
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

GlaxoSmithKline Plc
Celgene Corp
Biogen Inc
Amgen Inc
Seattle Genetics Inc
Johnson & Johnson
Merck Serono SA